RAFAEL
RUBIO GARCÍA
Profesor titular de universidad
![Foto de RAFAEL](/img/uploaded/6CA654DD031F6FEF08160B3A8AA5CC20.jpg)
![Foto de Hospital de Jerez](/img/noimage_org.png)
Hospital de Jerez
Jerez, EspañaPublications in collaboration with researchers from Hospital de Jerez (4)
2018
-
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial
Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2012
-
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial
Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968